Dhital R, Flint K, Kaptsan I, Hegde S, Daloul R, Shimamura M
J Immunol. 2024; 213(11):1703-1712.
PMID: 39423238
PMC: 11573647.
DOI: 10.4049/jimmunol.2300742.
Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y
Breast Cancer Res. 2024; 26(1):28.
PMID: 38360636
PMC: 10870674.
DOI: 10.1186/s13058-024-01785-x.
Field K, Wragg K, Kent S, Lee W, Juno J
Clin Transl Immunology. 2024; 13(2):e1486.
PMID: 38299190
PMC: 10825377.
DOI: 10.1002/cti2.1486.
Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Diaz R, Martinez-Perez A, Aguilar-Garcia C, Rodrigo J
Mol Cancer. 2023; 22(1):142.
PMID: 37649037
PMC: 10466776.
DOI: 10.1186/s12943-023-01845-4.
Zhang M, Lam K, Xu S
Front Immunol. 2023; 14:1207276.
PMID: 37638058
PMC: 10450036.
DOI: 10.3389/fimmu.2023.1207276.
Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis.
Preechanukul A, Kronsteiner B, Saiprom N, Rochaikun K, Moonmueangsan B, Phunpang R
iScience. 2023; 26(8):107234.
PMID: 37520720
PMC: 10372747.
DOI: 10.1016/j.isci.2023.107234.
Transcriptional reprogramming of natural killer cells by vaccinia virus shows both distinct and conserved features with mCMV.
Depierreux D, Smith G, Ferguson B
Front Immunol. 2023; 14:1093381.
PMID: 36911702
PMC: 9995584.
DOI: 10.3389/fimmu.2023.1093381.
CD160 receptor in CLL: Current state and future avenues.
Oumeslakht L, Aziz A, Bensussan A, Ben Mkaddem S
Front Immunol. 2022; 13:1028013.
PMID: 36420268
PMC: 9676924.
DOI: 10.3389/fimmu.2022.1028013.
CD160 Promotes NK Cell Functions by Upregulating Glucose Metabolism and Negatively Correlates With HIV Disease Progression.
Sun Z, Li Y, Zhang Z, Fu Y, Han X, Hu Q
Front Immunol. 2022; 13:854432.
PMID: 36110864
PMC: 9469471.
DOI: 10.3389/fimmu.2022.854432.
Human Hepatic CD56 NK Cells Display a Tissue-Resident Transcriptional Profile and Enhanced Ability to Kill Allogenic CD8 T Cells.
Jameson G, Harmon C, Santiago R, Houlihan D, Gallagher T, Lynch L
Front Immunol. 2022; 13:921212.
PMID: 35865550
PMC: 9295839.
DOI: 10.3389/fimmu.2022.921212.
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
Gauci M, Giustiniani J, Lepelletier C, Garbar C, Thonnart N, Dumaz N
Cancer Immunol Immunother. 2022; 71(11):2731-2742.
PMID: 35428910
PMC: 9519731.
DOI: 10.1007/s00262-022-03199-0.
Allosteric regulation of binding specificity of HVEM for CD160 and BTLA ligands upon G89F mutation.
Shrestha R, Garrett-Thomson S, Liu W, Almo S, Fiser A
Curr Res Struct Biol. 2021; 3:337-345.
PMID: 34917954
PMC: 8666650.
DOI: 10.1016/j.crstbi.2021.11.001.
Insights Into Human Intrahepatic NK Cell Function From Single Cell RNA Sequencing Datasets.
Jameson G, Robinson M
Front Immunol. 2021; 12:649311.
PMID: 33828559
PMC: 8019706.
DOI: 10.3389/fimmu.2021.649311.
Accelerator or Brake: Immune Regulators in Malaria.
Cai C, Hu Z, Yu X
Front Cell Infect Microbiol. 2020; 10:610121.
PMID: 33363057
PMC: 7758250.
DOI: 10.3389/fcimb.2020.610121.
Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
Shrestha R, Garrett-Thomson S, Liu W, Almo S, Fiser A
Structure. 2020; 28(11):1197-1205.e2.
PMID: 32795404
PMC: 7642093.
DOI: 10.1016/j.str.2020.07.013.
Mechanisms of activation of innate-like intraepithelial T lymphocytes.
Vandereyken M, James O, Swamy M
Mucosal Immunol. 2020; 13(5):721-731.
PMID: 32415229
PMC: 7434593.
DOI: 10.1038/s41385-020-0294-6.
Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms.
Ahmed El-Neanaey W, Swelem R, Ghallab O, Mohamed Abu-Shelou S
Int J Hematol Oncol Stem Cell Res. 2020; 14(1):27-37.
PMID: 32337012
PMC: 7167601.
CD160 expression on CD8 T cells is associated with active effector responses but limited activation potential in pancreatic cancer.
Liu S, Zhang W, Liu K, Wang Y
Cancer Immunol Immunother. 2020; 69(5):789-797.
PMID: 32055919
PMC: 11027829.
DOI: 10.1007/s00262-020-02500-3.
TIM-3 and TIM-1 Could Regulate Decidual TCR Bright T Cells during Murine Pregnancy.
Norenberg J, Meggyes M, Jakso P, Miko E, Barakonyi A
J Immunol Res. 2019; 2019:3836942.
PMID: 31236420
PMC: 6545878.
DOI: 10.1155/2019/3836942.
Structural Basis of CD160:HVEM Recognition.
Liu W, Garrett S, Fedorov E, Ramagopal U, Garforth S, Bonanno J
Structure. 2019; 27(8):1286-1295.e4.
PMID: 31230945
PMC: 7477951.
DOI: 10.1016/j.str.2019.05.010.